EcoDrugPlus

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSCPRG00005001801
Gene Symbol: WEE1
3 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSCPRG00005012732
Gene Symbol: YES1
3 Cross references
267 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Activin A Receptor Type 2b

Ensembl ID : ENSCPRG00005004570
Gene Symbol: ACVR2B
3 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A1 Receptor

Ensembl ID : ENSCPRG00005006061
Gene Symbol: ADORA1
3 Cross references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A2a Receptor

Ensembl ID : ENSCPRG00005002151
Gene Symbol: ADORA2A
3 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A2b Receptor

Ensembl ID : ENSCPRG00005013968
Gene Symbol: ADORA2B
3 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Deaminase

Ensembl ID : ENSCPRG00005011778
Gene Symbol: ADA
3 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Receptor A3-Like

Ensembl ID : ENSCPRG00005015844
Gene Symbol: LOC109317884
2 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Receptor A3-Like

Ensembl ID : ENSCPRG00005015841
Gene Symbol: LOC109317883
2 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1a

Ensembl ID : ENSCPRG00005014150
Gene Symbol: ADRA1A
3 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1b

Ensembl ID : ENSCPRG00005007082
Gene Symbol: ADRA1B
1 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1d

Ensembl ID : ENSCPRG00005018848
Gene Symbol: ADRA1D
1 Cross references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).